FDAnews
www.fdanews.com/articles/82267-guidant-updated-to-buy

GUIDANT UPDATED TO 'BUY'

November 8, 2005

Analyst Glenn Novarro of Banc of America Securities upgrades Guidant from "neutral" to "buy," while reducing his estimates for the company. The target price has been reduced from $69 to $66.
Newratings